Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study).
Cancer medicine（2023）
摘要
The RP2D of nab-paclitaxel as adjuvant chemotherapy in DGC was 260 mg/m . The AS regimen had a tolerable AE profile in stage III DGC.
更多查看译文
关键词
S-1,gastric cancer,maximal tolerated dose,nab-paclitaxel,phase I
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要